high mobility group box 1 pseudogene 17Genealiases: []
Q-omics provides the consensus-scored HMGB1P17 profile across patient tissues and cancer cell-line models. HMGB1P17 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HMGB1P17 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, HMGB1P17 RNA expression shows 6,459 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where HMGB1P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P17 survival associations across molecular data types. HMGB1P17 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P17 RNA expression–survival associations across cancer types. High HMGB1P17 expression shows unfavorable associations in KIRP and UVM, but favorable associations in STAD, SKCM, CESC and BLCA. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for HMGB1P17 RNA expression.
This table summarizes HMGB1P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P17 shows higher tumor expression in LUAD, STAD, HNSC, LUSC, BRCA and COAD. The LUAD box plot shows higher HMGB1P17 RNA expression in tumor versus normal tissue (log2 FC = +0.164, t-test p < 0.001).
This table shows molecular features associated with HMGB1P17 in patient tissues and cancer cell lines. In patient samples, HMGB1P17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
